{"analyses":[{"ciPctValue":"95","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0002","pValueComment":"The p value is two-sided from the log rank test which compares whether the azacitidine and control group follow the same duration curve.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.1","upperLimit":"16.3","value":"13.57"},{"groupId":"OG001","lowerLimit":"4.1","upperLimit":"9.7","value":"5.18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"51"}],"units":"Participants"}],"description":"The duration of improvement was defined as the time from the date of hematologic improvement until the date of first documented progression or relapse after hematologic improvement or death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Azacitidine, 75 mg/m\\^2/day given by subcutaneous injection for 7 days of every 28 day cycle, plus best supportive care.","id":"OG000","title":"Azacitidine"},{"description":"Physician choice of low dose cytarabine, standard chemotherapy, or best supportive care (consisting of blood products, growth factors, antibiotics)","id":"OG001","title":"Conventional Care"}],"paramType":"MEDIAN","populationDescription":"Intent to treat population. Participants showing hematologic improvement were 48 in azacitidine and 31 in conventional care.","reportingStatus":"POSTED","timeFrame":"Day 1 (randomization) to 42 months","title":"Duration of Any Hematologic Improvement","type":"SECONDARY","unitOfMeasure":"months"}